Todd Alfred Carter sold $14k of VYGR
Chief Scientific Officer at Voyager Therapeutics, Inc.. 3,305 shares at an average of $4.26, traded Feb 20, 2025, filed Feb 24, 2025.
Score components
- +15RoleOfficer
- 0Trade size$14k at market
- 0Share of holdings soldSold 4.1% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-016522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2025 | SOpen-market sale Common Stock | -3,305 | $4.26 | $14k | 77,718 | Feb 24, 2025 |
| Feb 21, 2025 | AGrant or award Common Stock | +46,000 | $0.00 | $0 | 123,718 | Feb 24, 2025 |
| Feb 21, 2025 | AGrant or award Stock Option (Right to Buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Feb 24, 2025 |
Related signals
Other insiders at Voyager Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Voyager Therapeutics, Inc. | Nathan D. Jorgensen Chief Financial Officer | $37k 7,666 shares | -6% | |
| 28Weak | VYGRsell Voyager Therapeutics, Inc. | Toby Ferguson Chief Medical Officer | $71k 19,000 shares | -12% | |
| 29Weak | Voyager Therapeutics, Inc. | Toby Ferguson Chief Medical Officer | $35k 10,086 shares | -6% | |
| 39Weak | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $37k 10,885 shares | -2% | |
| 23Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $24k 5,413 shares | -6% | |
| 23Weak | Voyager Therapeutics, Inc. | Sandell Jacquelyn Fahey Chief Legal Officer | $19k 4,358 shares | -5% | |
| 15Weak | VYGRsell Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $6,110 1,191 shares | -1% | |
| 26Weak | VYGRsell Voyager Therapeutics, Inc. | Robin Swartz COO&CBO | $37k 6,500 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.